General strategy for the generation of human antibody variable domains with increased aggregation resistance

Kip Dudgeon^{a,1}, Romain Rouet^{a,b,1}, Iris Kokmeijer^a, Peter Schofield^a, Jessica Stolp^a, David Langley^{a,c}, Daniela Stock^{b,c}, and Daniel Christ^{a,b,2}

^aGarvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia; ^bFaculty of Medicine, St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Sydney, New South Wales 2010, Australia; and ^cVictor Chang Cardiac Research Institute, 405 Liverpool Street, Darlinghurst, Sydney, New South Wales 2010, Australia

Edited by Alan R. Fersht, MRC Laboratory of Molecular Biology, Cambridge, United Kingdom, and approved May 29, 2012 (received for review February 21, 2012)

The availability of stable human antibody reagents would be of considerable advantage for research, diagnostic, and therapeutic applications. Unfortunately, antibody variable heavy and light domains (V_H and V_L) that mediate the interaction with antigen have the propensity to aggregate. Increasing their aggregation resistance in a general manner has proven to be a difficult and persistent problem, due to the high level of sequence diversity observed in human variable domains and the requirement to maintain antigen binding. Here we outline such an approach. By using phage display we identified specific positions that clustered in the antigen binding site (28, 30–33, 35 in V_H and 24, 49–53, 56 in V_L). Introduction of aspartate or glutamate at these positions endowed superior biophysical properties (non-aggregating, well-expressed, and heat-refoldable) onto domains derived from common human germline families (V_H3 and V_L1). The effects of the mutations were highly positional and independent of sequence diversity at other positions. Moreover, crystal structures of mutant V_H and V_L domains revealed a surprising degree of structural conservation, indicating compatibility with V_H/V_L pairing and antigen binding. This allowed the retrofitting of existing binders, as highlighted by the development of robust high affinity antibody fragments derived from the breast cancer therapeutic Herceptin. Our results provide a general strategy for the generation of human antibody variable domains with increased aggregation resistance.

biotechnology | monoclonal antibodies | protein aggregation | protein engineering | antibody therapeutics

Protein aggregation represents a key bottleneck in the generation of antibody-based reagents and hinders the development and production of human therapeutics (1). It is generally believed that the aggregation propensity of larger antibody reagents (such as immunoglobulin G and Fab) is mostly determined by their variable domain components (V_H and V_L), although there is currently little understanding of the mechanisms involved (1, 2). Indeed, significant differences of aggregation rates have been reported for antibodies that differ exclusively in their variable domains (1, 2). Aggregation propensity is even more pronounced for smaller antibody reagents, which lack the interdomain stabilization of their larger counterparts (3, 4). This is a major problem in biotechnology due to an increasing trend toward smaller antibody formats for imaging and tumor targeting applications (4). Common formats include human single chain fragments (scFv) and human single domain antibodies, both of which frequently display poor biophysical properties (1, 3).

The aggregation propensity of human variable domains is in marked contrast to the variable heavy domains of camels and llamas, which are generally nonaggregating and soluble (“ V_{HH} domains”) (5–7). More favorable properties have also been described for “camelized” and other engineered human V_H model domains (8–12) but not for human V_L domains. Their properties

have been attributed to extensive structural changes resulting in increased hydrophilicity of the V_H – V_L interface (8, 10, 12).

However, the relevance of observations in model V_H domains for the development of antibody reagents for real-world applications had so far remained unclear. In particular, high-affinity antigen binding has not been demonstrated (8, 11). Neither has pairing of the model domains with human V_L , a property also observed for camelid domains, which are naturally devoid of light chain partners (and for which analogous structural features in the former V_H – V_L interface have been reported) (8, 10–12). Moreover, human antibody variable domains are highly diverse and encompass multiple germline families for both heavy and light domains (13, 14). Even among variable domains derived from a single germline family considerable diversity is observed, predominantly within complementarity determining regions (CDR) (13–15). The high level of diversity affects aggregation propensity and biophysical properties of human variable domains. For instance, it has been demonstrated that both the choice of germline family and the composition of CDR3 have major influences on aggregation propensity (3). This is supported by reports from our laboratory indicating that preselection for aggregation-resistant V_H domains results in a reduction of CDR diversity by several orders of magnitude (16–18). As CDR3 mediates the majority of contacts with antigen (19), the question whether high affinity antigen binding and aggregation resistance are in fact mutually compatible had so far remained unanswered.

In this study we outline a general strategy for the generation of human antibody variable domains with increased aggregation resistance. We demonstrate its applicability to common human variable domain families and diverse antibody repertoires and present a report of human V_L domains with improved biophysical properties. Moreover, we present structural and mutational evidence demonstrating compatibility with high-affinity antigen binding.

Results

Phage Display Screen for Aggregation Preventing Mutations in Human Antibody Variable Domains. We utilized a high-throughput method

Author contributions: K.D., R.R., D.L., D.S., and D.C. designed research; K.D., R.R., I.K., P.S., J.S., D.L., and D.C. performed research; K.D., R.R., D.L., D.S., and D.C. analyzed data; and D.S. and D.C. wrote the paper.

Conflict of interest statement: K.D., R.R., and D.C. are named inventors on patents relating to this work and declare competing financial interests.

This article is a PNAS Direct Submission.

Data deposition: The atomic coordinates and structure factors have been deposited in the Protein Data Bank, www.pdb.org (PDB ID code 3UPC and 3UPA).

¹K.D. and R.R. contributed equally to this work.

²To whom correspondence should be addressed. E-mail: d.christ@garvan.org.au.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1202866109/-DCSupplemental.

on phage (20) to identify mutations that render human antibody variable domains resistant to aggregation. For our studies we chose variable domains that belong to families that are among the most common in the human repertoire (V_H3 , V_K1) (13, 14). These variable domain families are also prevalent among the 26 human monoclonal antibodies in clinical use and more than 350 currently in clinical trials (4, 21). Human V_H and V_L domains with amino acid substitutions at surface-exposed positions were displayed on phage. We targeted a wide range of positions while excluding CDR3 to limit effects on antigen binding. The domains were then heated and captured using protein A or L superantigens (which bind to folded but not to aggregated variable domains) (20, 22). Wild-type domains readily aggregated under such conditions (80 °C). However, this was not observed for several of the mutant domains, for which superantigen binding after heating was considerably improved (up to 40-fold for human V_H and 80-fold for human V_L) (Fig. 1 and Fig. S1). While we observed improvements when making both positively and negatively charged substitutions, by far the largest effect was observed for negatively charged substitutions (glutamate and, in particular, aspartate) (Fig. S2).

Mutations in the Antigen-Binding Site Control Aggregation Propensity of Common Human Variable Domain Families. Moreover, our experiments revealed that these effects were highly positional, highlighting specific sites that control aggregation resistance of the domains. In the case of human V_H such mutations clustered in CDR1 (H1), while mutations at other positions had little effect. Intriguingly, we discovered that this was not the case for human V_L : Here mutations strongly clustered in CDR2 (L2) (Fig. 1A and B). In total we identified six positions in H1 (28, 30, 31, 32,

33, 35) and five positions in L2 (50, 51, 52, 53, 56) that had major effects on aggregation resistance (in addition to two non-CDR positions at 24 and 49 of V_L). In addition to highlighting the positional nature of mutations, our experiments also demonstrated that their effects were largely additive, with combinations of mutations providing the highest levels of aggregation resistance (Fig. 1C). To demonstrate that our findings were more generally applicable, we next investigated the effect of mutations in H1 and L2 on antibody repertoires. For this purpose, we constructed synthetic phage display repertoires mimicking the CDR amino acid diversity in the human V_H (V_H3) and V_L (V_K1) repertoire (23). This revealed that the introduction of double aspartate substitutions into H1 of human V_H and L2 of human V_L significantly increased the mean aggregation resistance of the repertoires ($p < 0.001$) (Fig. 1D). We observed a dominant effect of mutations in H1 and L2: Thus, the observed aggregation resistance was largely independent of diversity at other CDR positions.

Human Variable Domains with Superior Biophysical Properties. Representative human variable domains were next expressed as soluble proteins to further assess their biophysical properties. As previously reported, human variable domains rapidly aggregate when heated to 80–85 °C, conditions well above their melting temperatures (20). In addition, they have a tendency to “stick” to gel filtration matrices, which hinders purification, and manifests itself through increased elution volumes (3, 20). Many human variable domains are also poorly expressed (3, 20). We observed that introduction of negatively charged substitutions (aspartate or glutamate) at H1 and L2 positions improved on all of the above properties. While unmodified human variable domains rapidly aggregated when subjected to heating, the mutant domains

Fig. 1. Effect of mutations in human antibody variable domains on aggregation resistance. Surface residues in variable heavy and light domains (human V_H3 , human V_K1) are targeted for substitution with aspartic acid (aspartate). Aggregation resistance of the domains is determined by measuring retained binding to superantigen after heating to 80 °C on phage (20). Mutations are mapped on the variable domain surface structure (blue: 100% retained binding; white: 0%; wild type residue: WT; means, standard deviation (SD) shown, $n = 2$). Numbering according to Kabat (30). Complementarity determining regions are indicated as H1, H2 for V_H and L1, L2 for V_L . (A) Single mutations in human V_H . (B) Single mutations in human V_L . (C) Double mutations in human V_H (Left) and human V_L (Right). (D) Mutations in human V_H repertoire (Left) and human V_L repertoire (Right). Synthetic repertoires closely mimicking CDR amino acid diversity in the natural antibody repertoire were generated (23). Mutant repertoires carry mutations in H1 (32D/33D) and L2 (52D/53D). Graph shows mean aggregation resistance of repertoires (***, $p < 0.001$).

Fig. 3. Crystal structures of mutant human variable domains: structure of triple mutants of (A) human V_H and (B) human V_L (in tan). CDR regions are shown in yellow/blue/red. Mutant residues are highlighted (sticks). The structures of the mutant domains tightly superpose onto structures of representative human variable domains [with the exception of H3 which is conformationally diverse in antibodies (40); representative structures shown in gray].

had indicated that the introduction of a large number (30–80) of charged substitutions at nonspecific surface positions can generate robust “supercharged” proteins (such as supercharged green fluorescent protein) (26). In marked contrast, the approach described here requires the introduction of only a handful of substitutions (two or more) at highly specific positions (28, 30, 31, 32, 33, 35 in V_H and 24, 49, 50, 51, 52, 53, 56 in V_L). Unlike supercharged proteins, many of the aggregation-resistant mutant variable domains carry no global net charge, highlighting the importance of localized charge (Fig. S4). We also observe a detectable preference for aspartate over glutamate and a strong preference for aspartate over lysine or arginine (Fig. S2). This indicates that properties other than charge also influence the observed aggregation resistance. While detailed mechanisms remain unclear, a preference for small negatively charged amino acids is apparent. The positional nature of our approach is further highlighted by the differences observed for human V_H and V_L with mutations clustering in CDR1 (H1) and CDR2 (L2), respectively (Fig. 1A and B). In contrast to human V_H , mutations in CDR1 have little effect on human V_L despite the fact that the domains are structurally closely related immunoglobulin folds.

The mutations reported here endow aggregation resistance onto domains derived from common germline families (13, 14), with V_H3 and $V_{\kappa}1$ representing approximately 40% and 32% of the rearranged repertoire (23). Importantly, we find that the effects of mutations in CDR H1 and L2 are not significantly influenced by diversity at other CDR positions (Fig. 1D). This is despite the fact that the expressed human variable domain repertoire is highly diverse (15). This is reflected by the synthetic repertoires studied here, which are extensively randomized at

between 9 ($V_{\kappa}1$) and 14 CDR positions (V_H3). The synthetic variable domain repertoires are designed to reflect natural sequence diversity within the human $V_{\kappa}1$ and V_H3 repertoire. Thus, we utilize preferentially rearranged human gene segments (V3-23/DP47, O12/O2/DPK9) (27, 28) and use trinucleotide phosphoramidite mutagenesis to match CDR amino acid distributions (29) (see *SI Text* for details). An alternative approach to repertoire diversity relies on the use of “consensus” sequences (rather than single common gene segments) (23). This strategy was used in the development of the Herceptin (V_H3 and $V_{\kappa}1$) variable domains (24) and is also clearly compatible with the mutational strategy outlined here (Fig. 3).

It is important to note that multiple mutations (two or more) are required to obtain considerable improvements of aggregation resistance in common biophysical assays (Fig. 2). The requirement for multiple positional substitutions may explain why effects on commercially important and widely studied immunoglobulin families had so far remained unnoticed. It also renders it unlikely that such mutations could be observed by chance within the natural repertoire. Thus, multiple aspartates or glutamates are not common at identified positions within the human V_H3 and $V_{\kappa}1$ germline repertoire and are notably absent from frequently utilized gene segments (such as V3–23) (27, 28). They are also not common in rearranged human antibody sequences (30), although exceptions exist [such as the Adalimumab (Humira) V_H domain] (31).

Our approach provides favorable characteristics among a range of biophysical properties. This includes considerable increases in expression yields, improved concentration, and purification. It also endows human variable domains with the capability

Fig. 4. Retrofitting of human variable domains (I): effects on biological activity of IgG. Variants of Trastuzumab (Herceptin) are generated by introduction of aspartate substitutions in CDR H1 and/or L2. Means, SD shown. (A) Binding to HER2 antigen on cells. The graph shows binding of IgG to SK-BR-3 breast cancer cells ($n = 2$). (B) Inhibition of cellular proliferation (as determined by incubation of SK-BR-3 cells with IgG; $n = 2$). (C) Serum concentrations (after intra-peritoneal injection of IgG into C57/BL6 mice at 1 mg/kg, $n = 4$).

clinical practice it has become evident that CDR mutations cause little or no immunogenicity in humans (39). In contrast, there is increasing evidence that the absence of aggregates is essential for the development of antibody therapeutics with low immunogenicity (1, 2). The method outlined here is therefore highly compatible with current antibody development strategies. This is exemplified by our work on variants of the antibody therapeutic Herceptin and highlights the potential of our method for “retro-fitting” approaches.

Conclusion

The availability of antibody reagents with improved aggregation resistance would be a significant advantage for research, diagnostic, and therapeutic applications. Consequently, the discovery of stable and nonaggregating V_H domains from camels and llamas has generated considerable interest and development efforts in recent years (4, 5). While such domains hold promise as robust and modular building blocks, their lack of light-chain partners

hinders the generation of multidomain antibody reagents; their nonhuman nature also complicates their use as therapeutics. In contrast, a general means for the development of robust human antibody domains had so far remained elusive. We conclude that our approach provides such a means for the generation of human antibody variable domains with increased aggregation resistance.

Methods

Generation of mutant variable domains and repertoires, analysis of aggregation resistance on phage, protein expression and purification, expression levels, elution volumes, refolding yields and turbidity measurements, crystal growth, structure solution, refinement and analysis, determination of thermodynamic stabilities, affinity measurements, cellular binding, inhibition of proliferation, and serum clearance are described in detail in *SI Text*.

ACKNOWLEDGMENTS. We thank staff at the Australian Synchrotron MX2 beamline for support and R. Brink, A. Basten, and J. Sprent for advice. This work was supported by the National Health and Medical Research Council and the Australian Research Council.

1. Lowe D, et al. (2011) Aggregation, stability, and formulation of human antibody therapeutics. *Adv Protein Chem Struct Biol* 84:41–61.
2. Demarest SJ, Glaser SM (2008) Antibody therapeutics, antibody engineering, and the merits of protein stability. *Curr Opin Drug Discov Devel* 11:675–687.
3. Ewert S, Huber T, Honegger A, Pluckthun A (2003) Biophysical properties of human antibody variable domains. *J Mol Biol* 325:531–553.
4. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. *Nat Biotechnol* 23:1126–1136.
5. Hamers-Casterman C, et al. (1993) Naturally occurring antibodies devoid of light chains. *Nature* 363:446–448.
6. Ewert S, Cambillau C, Conrath K, Pluckthun A (2002) Biophysical properties of camelid V (HH) domains compared to those of human V (H)3 domains. *Biochemistry* 41:3628–3636.
7. Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R (1994) Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. *Protein Eng* 7:1129–1135.
8. Barthelemy PA, et al. (2008) Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. *J Biol Chem* 283:3639–3654.
9. Christ D, Dudgeon K (2011) Modified Variable Domain Molecules and Methods for Producing and Using Same. WO/2011/047442 (April 04, 2011).
10. Jaspers L, Schon O, James LC, Veprintsev D, Winter G (2004) Crystal structure of HEL4 a soluble, refoldable human V(H) single domain with a germ-line scaffold. *J Mol Biol* 337:893–903.
11. Perchiacca JM, Bhattacharya M, Tessier PM (2011) Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions. *Proteins* 79:2637–2647.
12. Riechmann L (1996) Rearrangement of the former VL interface in the solution structure of a camelized, single antibody VH domain. *J Mol Biol* 259:957–969.
13. Cox JP, Tomlinson IM, Winter G (1994) A directory of human germ-line V kappa segments reveals a strong bias in their usage. *Eur J Immunol* 24:827–836.
14. Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G (1992) The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. *J Mol Biol* 227:776–798.
15. Tomlinson IM, et al. (1996) The imprint of somatic hypermutation on the repertoire of human germline V genes. *J Mol Biol* 256:813–817.
16. Christ D, Famm K, Winter G (2006) Tapping diversity lost in transformations—In vitro amplification of ligand reactions. *Nucleic Acids Res* 34:e108.
17. Christ D, Famm K, Winter G (2007) Repertoires of aggregation-resistant human antibody domains. *Protein Eng Des Sel* 20:413–416.
18. Dudgeon K, Famm K, Christ D (2009) Sequence determinants of protein aggregation in human VH domains. *Protein Eng Des Sel* 22:217–220.
19. MacCallum RM, Martin AC, Thornton JM (1996) Antibody–antigen interactions: Contact analysis and binding site topography. *J Mol Biol* 262:732–745.
20. Jaspers L, Schon O, Famm K, Winter G (2004) Aggregation-resistant domain antibodies selected on phage by heat denaturation. *Nat Biotechnol* 22:1161–1165.
21. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. *Nat Rev Drug Discov* 9:767–774.
22. Jansson B, Uhlen M, Nygren PA (1998) All individual domains of staphylococcal protein A show Fab binding. *FEMS Immunol Med Microbiol* 20:69–78.
23. Knappik A, et al. (2000) Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. *J Mol Biol* 296:57–86.
24. Carter P, et al. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. *Proc Natl Acad Sci USA* 89:4285–4289.
25. Bostrom J, et al. (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. *Science* 323:1610–1614.
26. Lawrence MS, Phillips KJ, Liu DR (2007) Supercharging proteins can impart unusual resilience. *J Am Chem Soc* 129:10110–10112.
27. Suzuki I, Pfister L, Glas A, Nottenburg C, Milner EC (1995) Representation of rearranged VH gene segments in the human adult antibody repertoire. *J Immunol* 154:3902–3911.
28. Foster SJ, Brezinschek HP, Brezinschek RI, Lipsky PE (1997) Molecular mechanisms and selective influences that shape the kappa gene repertoire of IgM+ B cells. *J Clin Invest* 99:1614–1627.
29. Virnekas B, et al. (1994) Trinucleotide phosphoramidites: Ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis. *Nucleic Acids Res* 22:5600–5607.
30. Kabat E, Wu TT, Perry HM, Kay S, Gottesman CF (1992) *Sequences of Proteins of Immunological Interest* (Diane Publishing, Darby, PA), 5th Ed, p 2719.
31. Wang X, Das TK, Singh SK, Kumar S (2009) Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. *MAbs* 1:254–267.
32. Ewert S, Honegger A, Pluckthun A (2003) Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach. *Biochemistry* 42:1517–1528.
33. Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM (2003) Rationalization of the effects of mutations on peptide and protein aggregation rates. *Nature* 424:805–808.
34. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. *Nature* 321:522–525.
35. Kelley RF, O’Connell MP (1993) Thermodynamic analysis of an antibody functional epitope. *Biochemistry* 32:6828–6835.
36. Cho HS, et al. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. *Nature* 421:756–760.
37. Schaefer JV, Pluckthun A (2012) Engineering aggregation resistance in IgG by two independent mechanisms: Lessons from comparison of *Pichia pastoris* and mammalian cell expression. *J Mol Biol* 417:309–335.
38. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC (2005) Monoclonal antibody successes in the clinic. *Nat Biotechnol* 23:1073–1078.
39. Hwang WY, Foote J (2005) Immunogenicity of engineered antibodies. *Methods* 36:3–10.
40. Chothia C, Lesk AM (1987) Canonical structures for the hypervariable regions of immunoglobulins. *J Mol Biol* 196:901–917.